Online inquiry

IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9228MR)

This product GTTS-WQ9228MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MUC1 gene. The antibody can be applied in Pancreatic Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001018016.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4582
UniProt ID P15941
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9228MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6036MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CNTO 136
GTTS-WQ7175MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ7554MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GC33
GTTS-WQ206MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 13C5.5
GTTS-WQ599MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 6A3-IgG4
GTTS-WQ9333MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ8286MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HM10560A
GTTS-WQ11913MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MLN-1202
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW